<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276770</url>
  </required_header>
  <id_info>
    <org_study_id>27318</org_study_id>
    <secondary_id>UW-6230</secondary_id>
    <secondary_id>NCI-7223</secondary_id>
    <nct_id>NCT00276770</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas</brief_title>
  <official_title>NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography using fluorothymidine&#xD;
      F 18, may be effective in finding recurrent disease in patients with gliomas.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well positron emission tomography using&#xD;
      fluorothymidine F 18 works in finding recurrent disease in patients with gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of fluorothymidine F 18 for visual and dynamic brain tumor images&#xD;
           in patients with glial neoplasms.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare, preliminarily, the efficacy of this drug to fludeoxyglucose F 18 in&#xD;
           differentiating tumor recurrence from radiation necrosis.&#xD;
&#xD;
        -  Determine the optimal time to image post injection of this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot, nonrandomized study.&#xD;
&#xD;
      Patients receive fluorothymidine F 18 IV over 1 minute and then undergo positron emission&#xD;
      tomography (PET) scanning of the brain over 2 hours.&#xD;
&#xD;
      After completion of the PET scan, patients are followed for at least 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">12</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorine F 18 fluorothymidine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Radiological or established histological diagnosis of glioma&#xD;
&#xD;
               -  WHO grade 2-4 disease&#xD;
&#xD;
          -  Presence of a new or enlarging enhancing lesion on gadolinium-enhanced MRI after prior&#xD;
             radiotherapy&#xD;
&#xD;
               -  Differentiation of recurrent tumor from radiation necrosis is not possible&#xD;
&#xD;
          -  No clinically significant signs of uncal herniation, including any of the following:&#xD;
&#xD;
               -  Acute pupillary enlargement&#xD;
&#xD;
               -  Rapidly developing (i.e., over hours) motor changes&#xD;
&#xD;
               -  Rapidly decreasing level of consciousness&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Gamma-glutamyl-transferase ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ 2 times ULN&#xD;
&#xD;
          -  Direct and total bilirubin normal&#xD;
&#xD;
          -  Amylase normal&#xD;
&#xD;
          -  Haptoglobin normal&#xD;
&#xD;
          -  Serum electrolytes normal&#xD;
&#xD;
          -  CBC with platelets normal&#xD;
&#xD;
          -  PT, PTT normal&#xD;
&#xD;
          -  BUN and creatinine normal&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
          -  Urinalysis normal&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Female patients must be postmenopausal for ≥ 1 year or surgically sterile, or on 1 of&#xD;
             the following methods of birth control for ≥ 1 month: IUD, oral contraceptives,&#xD;
             Depo-Provera, or Norplant&#xD;
&#xD;
               -  These criteria can be waived at the discretion of the investigator if the&#xD;
                  patient's intracranial tumor is considered life threatening and the 1-month wait&#xD;
                  required is not in the best interest of the patient&#xD;
&#xD;
          -  No known allergic or hypersensitivity reactions to previously administered&#xD;
             radiopharmaceuticals&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  Not requiring monitored anesthesia for positron emission tomography scanning&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Concurrent biopsy or neurosurgical procedure for diagnostic and/or therapeutic&#xD;
             purposes for this cancer allowed&#xD;
&#xD;
          -  Concurrent surgery for this cancer allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander M. Spence, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol. 2008 Sep;10(5):271-80. doi: 10.1007/s11307-008-0151-6. Epub 2008 Jun 10.</citation>
    <PMID>18543042</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult mixed glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

